🚀 VC round data is live in beta, check it out!
BioKangtai Valuation Multiples
Discover revenue and EBITDA valuation multiples for BioKangtai and similar public comparables like Pfizer India, AstraZeneca Pharma India, Dianthus Therapeutics, Ocular Therapeutix and more.
BioKangtai Overview
About BioKangtai
Shenzhen Kangtai Biological Products Co Ltd is a human vaccine research and development company. The company is engaged in the research and development, production and sales of recombinant hepatitis B vaccine, b -type influenza Haemophilus conjugate vaccine, measles-rubella combined live attenuated vaccine, cell-free baibai broke b Haemophilus influenzae vaccine and other products.
Founded
1992
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$2B
BioKangtai Financials
BioKangtai reported last 12-month revenue of $417M and EBITDA of $116M.
In the same LTM period, BioKangtai generated $116M in EBITDA and $20M in net income.
Revenue (LTM)
BioKangtai P&L
In the most recent fiscal year, BioKangtai reported revenue of $381M and EBITDA of $99M.
BioKangtai expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $417M | XXX | $381M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $313M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 82% | XXX | XXX | XXX |
| EBITDA | $116M | XXX | $99M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $20M | XXX | $29M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | — | — | $200M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioKangtai Stock Performance
BioKangtai has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
BioKangtai's stock price is $2.14.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.9% | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioKangtai Valuation Multiples
BioKangtai trades at 5.8x EV/Revenue multiple, and 20.8x EV/EBITDA.
EV / Revenue (LTM)
BioKangtai Financial Valuation Multiples
As of March 18, 2026, BioKangtai has market cap of $2B and EV of $2B.
Equity research analysts estimate BioKangtai's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioKangtai has a P/E ratio of 121.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 5.8x | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBITDA | 20.8x | XXX | 24.5x | XXX | XXX | XXX |
| EV/EBIT | 65.6x | XXX | 35.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 7.7x | XXX | XXX | XXX |
| P/E | 121.1x | XXX | 82.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 125.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BioKangtai Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BioKangtai Margins & Growth Rates
BioKangtai's revenue in the last 12 month grew by 17%.
BioKangtai's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioKangtai's rule of X is 70% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
BioKangtai Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 70% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 32% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BioKangtai Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pfizer India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca Pharma India | XXX | XXX | XXX | XXX | XXX | XXX |
| Dianthus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ocular Therapeutix | XXX | XXX | XXX | XXX | XXX | XXX |
| HUTCHMED (China) | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioKangtai M&A Activity
BioKangtai acquired XXX companies to date.
Last acquisition by BioKangtai was on XXXXXXXX, XXXXX. BioKangtai acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BioKangtai
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioKangtai Investment Activity
BioKangtai invested in XXX companies to date.
BioKangtai made its latest investment on XXXXXXXX, XXXXX. BioKangtai invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BioKangtai
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BioKangtai
| When was BioKangtai founded? | BioKangtai was founded in 1992. |
| Where is BioKangtai headquartered? | BioKangtai is headquartered in China. |
| Is BioKangtai publicly listed? | Yes, BioKangtai is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of BioKangtai? | BioKangtai trades under 300601 ticker. |
| When did BioKangtai go public? | BioKangtai went public in 2017. |
| Who are competitors of BioKangtai? | BioKangtai main competitors are Pfizer India, AstraZeneca Pharma India, Dianthus Therapeutics, Ocular Therapeutix. |
| What is the current market cap of BioKangtai? | BioKangtai's current market cap is $2B. |
| What is the current revenue of BioKangtai? | BioKangtai's last 12 months revenue is $417M. |
| What is the current revenue growth of BioKangtai? | BioKangtai revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of BioKangtai? | Current revenue multiple of BioKangtai is 5.8x. |
| Is BioKangtai profitable? | Yes, BioKangtai is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BioKangtai? | BioKangtai's last 12 months EBITDA is $116M. |
| What is BioKangtai's EBITDA margin? | BioKangtai's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of BioKangtai? | Current EBITDA multiple of BioKangtai is 20.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.